| Literature DB >> 25837376 |
Ruchira Sen1, Rhitoban Raychoudhury1, Yunpeng Cai2, Yijun Sun2, Verena-Ulrike Lietze3, Brittany F Peterson1, Michael E Scharf1, Drion G Boucias3.
Abstract
Previous studies in lower termites revealed unexpected synergies between nicotinoid insecticides and fungal entomopathogens. The present study investigated molecular mechanisms of nicotinoid-pathogen synergy in the lower termite Reticulitermes flavipes, using the nicotinoid, imidacloprid, in combination with fungal and bacterial entomopathogens. Particular focus was placed on metatranscriptome composition and microbial dynamics in the symbiont-rich termite gut, which houses diverse mixes of protists and bacteria. cDNA microarrays containing a mix of host and protist symbiont oligonucleotides were used to simultaneously assess termite and protist gene expression. Five treatments were compared that included single challenges with sublethal doses of fungi (Metharizium anisopliae), bacteria (Serratia marcescens) or imidacloprid, and dual challenges with fungi + imidacloprid or bacteria + imidacloprid. Our findings point towards protist dysbiosis and compromised social behavior, rather than suppression of stereotypical immune defense mechanisms, as the dominant factors underlying nicotinoid-pathogen synergy in termites. Also, greater impacts observed for the fungal pathogen than for the bacterial pathogen suggest that the rich bacterial symbiont community in the R. flavipes gut (>5000 species-level phylotypes) exists in an ecological balance that effectively excludes exogenous bacterial pathogens. These findings significantly advance our understanding of antimicrobial defenses in this important eusocial insect group, as well as provide novel insights into how nicotinoids can exert deleterious effects on social insect colonies.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25837376 PMCID: PMC4383478 DOI: 10.1371/journal.pone.0123391
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Microarray treatment summary: F (fungi), I (imidacloprid), B (bacteria), F+I (fungus + imidacloprid), B+I (bacteria + imidacloprid), and SC (solvent control) treatments.
Reported analyses consisted of five pairwise comparisons to a common control, as denoted by the numbers 1–5.
Fig 2Representative examples of normal and infected termites.
(A,B) Control termites displaying normal behaviors and (C,D) imidacloprid treated termites displaying mild intoxication effects. (E,F) Termites treated with sublethal fungal dose showing no effects, and (G,H) termites displaying mycosis after treatment with fungi + imidacloprid. (I) Termites treated with bacteria + imidacloprid showing varying degrees of Serratia infection.
Fig 3Bioassay mortality after 7 day exposures to six treatments.
Highest mortality occurred in combination treatments of fungi + imidacloprid and bacteria + imidacloprid (see Fig. 1 for treatment abbreviations). Kruskal-Wallis (K-W) test statistics are shown indicating significance of the whole model. Bars with the same letters (a,b,c) are not different by Mann-Whitney U-tests (p<0.05).
Fig 4Microarray volcano plots showing differing numbers of passing array positions in F (fungi), I (imidacloprid), B (bacteria), F+I (fungus + imidacloprid), B+I (bacteria + imidacloprid) treatments.
Red and blue spots indicate significant upregulated and downregulated array positions with +/- 2-fold change (FC) upregulation and downregulation, respectively.
Summary table showing up- and downregulated contigs and “singletons” from host and symbiont in each treatment category (F, B, I, F+I and B+I).
| UPREGULATED | DOWNREGULATED | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Host | Symbiont | mixed | Totals | Host | Symbiont | mixed | Totals | Overall | |
|
| 56 | 12 | 1 | 69 | 6 | 8 | 0 | 14 |
|
|
| 142 | 13 | 1 | 156 | 6 | 34 | 0 | 40 |
|
|
| 157 | 19 | 1 | 177 | 8 | 205 | 3 | 216 |
|
|
| 568 | 48 | 3 | 619 | 42 | 567 | 7 | 616 |
|
|
| 634 | 63 | 4 | 701 | 26 | 545 | 8 | 579 |
|
|
| 1557 | 155 | 10 | 1722 | 88 | 1359 | 18 | 1465 |
|
Overall, greater numbers of host genes were upregulated and symbiont genes were downregulated by the various treatments. “Mixed” refers to genes that were sampled from both host and symbiont libraries.
A subset of upregulated (values >1) and downregulated (values <1) candidate genes identified across all microarray treatment categories (F, B, I, F+I and B+I) and their origins from either host or symbiont (see text for details).
| Fold change (by treatment) | |||||||
|---|---|---|---|---|---|---|---|
| Category | Candidate genes | F | B | I | F+I | B+I | Origin |
|
| antimicrobial peptide 7848 | 1.41 | Host | ||||
| cathepsin b | 0.423 | Symbiont | |||||
| ferric-chelate reductase 1 | 1.34 | Host | |||||
| heat shock protein | 0.271 | Symbiont | |||||
| heat shock protein | 0.261 | 2.59 | Symbiont | ||||
| heat shock protein 90 | 2.67 | Symbiont | |||||
| laccase 2 | 1.37 | Host | |||||
| lysozyme p | 1.43 | Host | |||||
| lysozyme precursor | 1.67 | Host+Symbiont | |||||
| peptidoglycan recognition partial | 1.77 | Host | |||||
| peptidoglycan-recognition protein s2 | 1.81 | Host | |||||
| termicin | 1.39 | Host | |||||
| transferrin | 1.31 | Host | |||||
| transferrin 3 | 1.50 | Symbiont | |||||
| alpha amylase | 1.69 | Host | |||||
| cell surface leucine-rich repeat-containing protein | 1.23 | 1.25 | Host | ||||
| leucine-rich repeat-containing protein | 0.68 | 2.08 | Symbiont | ||||
| leucine rich repeat family | 0.74 | 1.46 | Symbiont | ||||
| leucine-rich repeat-containing protein 48 | 0.73 | 1.88 | Symbiont | ||||
| leucine rich repeat protein 1 | 0.64 | 1.44 | Symbiont | ||||
| leucine rich repeat family protein | 0.71 | 1.72 | Symbiont | ||||
| leucine rich repeat family | 1.49 | Symbiont | |||||
| leucine-rich repeat-containing protein 56 | 1.74 | Symbiont | |||||
| leucine rich repeat family | 1.48 | Symbiont | |||||
|
| alpha—mannosyl-glycoprotein 2-beta-n-acetyl-glucosaminyltransferase | 1.36 | Host | ||||
| beta-galactosidase-like | 1.33 | 1.29 | 1.48 | Host | |||
| GHF 1 (beta-glucosidase) | 1.28 | 1.32 | Symbiont | ||||
| beta-lactamase | 0.550 | Symbiont | |||||
| brain chitinase and chia | 1.24 | Host | |||||
| carbohydrate-binding protein | 0.715 | Host | |||||
| chitinase-like protein idgf4-like | 1.19 | Host | |||||
| c-type lectin precursor | 0.66 | Host | |||||
| dockerin | 0.77 | 0.545 | 1.57 | Symbiont | |||
| endo—beta-d-glucanase | 1.33 | Symbiont | |||||
| GHF 3 | 0.466 | Symbiont | |||||
| GHF 3 N-terminal domain protein | 0.67 | 1.78 | Symbiont | ||||
| GHF 10 | 0.733 | Symbiont | |||||
| GHF 7 | 0.80 | 0.76 | 0.001 | 1.61 | Symbiont | ||
| GHF 7 | 0.480 | 1.71 | Symbiont | ||||
| GHF 7 | 0.572 | 1.51 | Symbiont | ||||
| GHF 7 | 0.552 | 1.51 | Symbiont | ||||
| GHF 7 | 0.508 | Symbiont | |||||
| GHF 7 | 0.832 | Symbiont | |||||
| GHF 7 | 0.786 | Symbiont | |||||
| GHF 7 | 0.536 | Symbiont | |||||
| GHF 13 (maltase 2) | 1.22 | Host | |||||
| maltase a2 | 1.26 | Host | |||||
|
| takeout family protein | 1.20 | 1.21 | Host | |||
| takeout family protein | 1.20 | Host | |||||
| takeout family protein | 1.23 | Host | |||||
| takeout family protein | 1.20 | Host | |||||
| takeout family protein(JHBP like) | 1.25 | Host | |||||
|
| abc transporter family protein | 0.551 | 1.54 | Symbiont | |||
| abc transporter family protein | 0.545 | 1.68 | Symbiont | ||||
| catalase | 1.20 | Host | |||||
| epoxide hydrolase 4-like | 0.81 | Host | |||||
| multidrug resistance protein 2 | 2.46 | Symbiont | |||||
| peroxidase ppod1 | 2.39 | Symbiont | |||||
|
| 50 Kda midgut protein | 2.09 | 1.95 | 2.30 | Host | ||
| insulin receptor | 1.36 | 1.29 | Host | ||||
| JH-inducible protein | 1.50 | 1.46 | Host | ||||
| nli interacting factor-like phosphatase family protein | 2.37 | 0.36 | Host | ||||
| tyramine beta hydroxylase | 1.42 | Host | |||||
| arylsulfatase j-like | 1.24 | Host | |||||
|
| allatostatin neuropeptide precursor | 1.27 | 1.50 | Host | |||
| neuropeptide f | 1.26 | Host | |||||
|
| CYP304A1-like | 1.23 | 1.43 | Host | |||
| CYP4C1-like | 1.24 | 1.24 | 1.25 | Host | |||
| Cyp4C1-like | 1.21 | 1.25 | Host | ||||
| CYP6AM1-like | 1.26 | 1.27 | 1.35 | Host | |||
| CYP6K1-like | 1.22 | Host | |||||
| CYP9E2-like | 1.30 | 1.34 | Host | ||||
| CYP9E2-like | 1.20 | Host | |||||
| CYP15F1 ( | 1.19 | Host | |||||
| CYP4U3V1 ( | 1.22 | Host | |||||
|
| EF hand family protein | 2.48 | Symbiont | ||||
| fork head | 1.22 | Host | |||||
| RNA-binding protein luc7-like 2-like | 1.60 | 1.47 | Host | ||||
|
| cysteine synthase a | 0.46 | 0.301 | Symbiont | |||
See S1–S5 Tables for a full listing of significant responsive genes from each treatment category.